Bioavailability Study Comparing Two New Nilotinib Tablet Formulations to an Established Nilotinib Capsule Formulation in Healthy Volunteers
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 55 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Healthy adult male (18 - 55 yrs) and sterile or post menopausal female subjects
Body weight must be ≥50 kg and <100 kg, with a body mass index (BMI) >18 but <33.
Laboratory parameter values must fall within the normal range
Female who is pregnant or breast feeding.
Contraindication to receiving nilotinib.
Smokers or user of tobacco products
A past medical history of clinically significant Electrocardiogram abnormalities, or a history/family history of long QT-interval syndrome.
Other protocol-defined inclusion/exclusion criteria may apply